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Background: Although Mycoplasma pneumoniae (MP) is a common cause of
community-acquired pneumonia (CAP) in children, the currently used diagnostic
methods are not optimal. Proteomics is increasingly being used to study the biomarkers
of infectious diseases.
Methods: Label-free quantitative proteomics and liquid chromatography-mass/mass
spectrometry were used to analyze the fold change of protein expression in plasma of
children with MP pneumonia (MPP), infectious disease control (IDC), and healthy control
(HC) groups. Selected proteins that can distinguish MPP from HC and IDC were further
validated by enzyme-linked immunosorbent assay (ELISA).
Results: After multivariate analyses, 27 potential plasma biomarkers were identified
to be expressed differently among child MPP, HC, and IDC groups. Among these
proteins, SERPINA3, APOC1, ANXA6, KNTC1, and CFLAR were selected for ELISA
verification. SERPINA3, APOC1, and CFLAR levels were significantly different among
the three groups and the ratios were consistent with the trends of proteomics results.
A comparison of MPP patients and HC showed APOC1 had the largest area under the
curve (AUC) of 0.853, with 77.6% sensitivity and 81.1% specificity. When APOC1 levels
were compared between MPP and IDC patients, it also showed a relatively high AUC of
0.882, with 77.6% sensitivity and 85.3% specificity.
Conclusion: APOC1 is a potential biomarker for the rapid and noninvasive diagnosis of
MPP in children. The present finding may offer new insights into the pathogenesis and
biomarker selection of MPP in children.
Keywords: plasma proteins, Mycoplasma pneumoniae, children, label-free quantitative proteomics, APOC1
INTRODUCTION
Mycoplasma pneumoniae (MP), the smallest free-living organism, is a common cause of upper
and lower respiratory tract infections (Sanchez-Vargas and Gomez-Duarte, 2008). MP pneumonia
(MPP) causes up to 40% of community-acquired pneumonia (CAP) in children and this is even
higher ratio during epidemics. Although it is a self-limiting disease, some cases develop into
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refractory or fulminant pneumonia that can threaten the lives of
children (Waites and Talkington, 2004).
The pathophysiology of MP infection is complex and the
underlying molecular mechanisms are reported to be associated
with many proteins. MP infection is thought to influence the
expression of associated proteins, which are released into the
bloodstream through different pathways (Covani et al., 2008; Sun
et al., 2008; Li et al., 2014). Plasma proteins including cytokines,
growth factors, extracellular matrix proteins, and other soluble
mediators are essential for MP infection. In terms of pediatric
MPP diagnosis, culture and serological tests are insensitive, time-
consuming, and cross-reactive in children (Daxboeck et al., 2003;
Long et al., 2012); therefore, they are not appropriate for the rapid
and accurate detection of MP infection in clinical practice.
In general, detecting biomarkers in the plasma is a useful
auxiliary method to diagnosis disease (Chen et al., 2013; Meyer
Sauteur et al., 2014; Shu et al., 2015). Recently, advances in
high-throughput technologies, such as proteomics, have made
the analysis of plasma proteins possible (Li et al., 2014).
Proteomic analysis using a label-free protocol is increasingly
being performed for biomarker selection. Based on the principle
that a special mixture of plasma proteins present different
characterizations, this technique has been widely used in many
diseases including infectious diseases (Papadopoulos et al., 2004;
Ren et al., 2004; Agranoff et al., 2006; Hodgetts et al., 2007),
cancer (Engwegen et al., 2006), and vascular disease (Pinet et al.,
2008; Zhang et al., 2008; Hong et al., 2009). Although many
protein biomarkers of MPP have been indicated by proteomics,
specific proteins that can be used to discriminate MPP from
other infection diseases, especially in children, have not been fully
elucidated.
In this study, we analyzed the fold change of protein
expression of children with MPP, infectious disease controls
(IDC), and healthy controls (HC) using label-free quantitative
proteomics and liquid chromatography-mass/mass spectrometry
(LC-MS/MS). Proteins identified that could distinguish MPP
from HC and IDC were further validated by enzyme-linked
immunosorbent assay (ELISA). The aim of this study was to
screen potential protein biomarkers in plasma from children that
could be used to distinguish MPP from HC and IDC.
MATERIALS AND METHODS
Patients and Controls
This study was performed in the Beijing Children’s Hospital
from November 2014 to September 2015. During the first
period, a total of 20 children hospitalized with a final diagnosis
of MPP confirmed in serum samples using PCR and ELISA
were enrolled. Symptoms of children included fever, acute
respiratory symptoms (cough, tachypnoea, difficult breathing) or
both (Tamura et al., 2008; Wang et al., 2014). Seventeen other
children defined as IDC were collected accordingly and had
symptoms including respiratory symptoms and negative MPP
immunoglobulin (Ig) M (<1:80) to exclude MPP. HC group
subjects (n = 20) were recruited from children undergoing
physical examination in Beijing Children’s Hospital from
November 2014 to May 2015. Patients with immunosuppression
and those who received immunosuppressive therapy were
excluded. All the groups were matched by age, gender, and
ethnicity.
Protein Extraction
Human plasma with the removal of IgG, IgA, albumin,
antitrypsin, haptoglobin, and transferrin, were mixed together
for each group and divided into three tubes which were tested
respectively. Each mixed sample was suspended with phosphate
buffered saline (PBS, 50 µL), centrifuged at 10,000 × g for 30
min in 4◦C, and suspended in 100 µL lysis buffer (7 M urea, 2
M thiourea). After being centrifuged at 40,000 × g for 30 min,
proteins were extracted by ultrasonic sonication and precipitated
with trichloroacetic acid for 30 min on ice. Then, samples were
diluted with 50 mM NH4HCO3 to a final concentration of 0.5
mg/mL, and each sample was mixed with DTT (5 µL, 1 mol/L)
at 37◦C for 60 min, diluted with IAA (20 µL, 1 mol/L) for 60
min in the dark, and digested with trypsin at 37◦C for 12 h. The
digested supernatant fractions were used for LC-MS/MS analysis
(Lee et al., 2015).
LC-MS/MS Analysis
Peptide mixtures were subjected to nano-liquid chromatography
associated with MS for protein identification. All of the mass
analyses were performed using a LC-MS/MS system, which
consisted of an Agilent 1100 quaternary HPLC (Agilent, EASY-
nLC1000, USA) and a Q-Exactive mass spectrometer (Thermo
Finnigan, Germany) with the application of a distal 180◦C source
temperature. An RP trap column (Thermo EASY column SC200,
150 µm × 100 mm) and a C18 reverse-phase column (Thermo
EASY column SC001 traps, 150 µm × 20 mm) was used for
desalting and separating samples, respectively. Mobile phase A
consisted of HPLC-grade water containing 0.1% formic acid
(FA), and phase B consisted of 84% HPLC-grade acetonitrile
(ACN) containing 0.1% FA. The analytical separation was run at
a flow rate of 400 nl/min by using a linear gradient of phase B as
follows: 0–45% for 100 min, 45–100% for 8 min, and 100% for 12
min. Each LC-MS/MS analysis was repeated three times to reduce
technical variation (Lee et al., 2015).
Bioinformatics Analysis
For protein identification, we used the Mascot 2.1 program
(Matrix science) to search fragmentation spectra against a human
database. For full MS or MS/MS spectra searches, an error of six
parts per million (ppm) or 20 ppm was set, respectively, and two
missed cleavages were allowed. Peptide mass tolerance was set
to 0.5 Da, fragment mass tolerance was set to 10 ppm. Variable
modification was oxidation of methionine, static modification
was carbamidomethylation of cysteine. Protein identification was
considered valid if at least one peptide and the p < 0.05, the
proteins not satisfying these defined criteria were rejected, the
threshold for accepting MS/MS spectra was false discovery rate
(FDR) 0.05. The Maxquant MS Analysis Software was used
to estimate the fold-changes in the level of identified proteins
between the three groups.
A Web-accessible resource (Version 2.0) was used to
determine the over-representation of Gene Ontology (GO)
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categories, which was classified on the basis of cellular
component (CC), molecular function (MF), and biological
process (BP) (Zhang et al., 2014; Wu et al., 2016). Signaling
pathway analysis was performed using tools from the Kyoto
Encyclopedia of Genes and Genome (KEGG) database (http://
www.genome.jp/kegg/pathway.html) (Kanehisa et al., 2004). A
network model of protein interactions according to known
protein-protein interactions was made using Retrieval of
Interacting Genes (STRING) 9.05.
ELISA
ELISA was used to quantify the concentrations of the selected
plasma proteins. Human alpha-1-antichymotrypsin precursor
(SERPINA3) (RayBiotech), human kinetochore-associated
protein 1 (KNTC1) (Dldevelop), human apolipoprotein
C-I precursor (APOC1) (RayBiotech), human annexin A6
isoform 2 (ANXA6) (Abnova), and CASP8 and FADD-like
apoptosis regulator isoform 6 (CFLAR) (Dldevelop) ELISA
kits were used to measure the changes in plasma protein
levels in the MPP (n = 85), HC (n = 95), and IDC (n = 75)
groups. ELISAs were performed according to each kit’s
instructions.
Statistical Analysis
Each experiment was independently repeated at least three
times. Data were expressed as the mean ± SD and evaluated
by Student’s t-test. P < 0.05 was considered statistically
significant.
Statistical analysis was performed using MetaboAnalyst 3.0
(Biomarker Analysis).
Classical univariate receiver operating characteristic (ROC)
curve analyses to generate ROC curves, calculate the area under
the curve (AUC) and 95% confidence intervals, compute optimal
cutoffs for any given feature, and to generate performance
tables for sensitivity, specificity, and confidence intervals at
different cutoffs were performed. ROC curve analyses were
performed based on three multivariate algorithms—support
vector machines, which were used to assess the diagnostic value
of candidate proteins.
Ethics Statement
This research was approved by the Ethics Committee of Beijing
Children’s Hospital (Supplementary Table 1). Written informed
consent was collected from the children or the guardians of
children. In accordance with the Declaration of Helsinki and
the local ethics committee requirements, the plasma collection
protocol in this research was based on the following standards:
(1) Potential risk of the minor discomfort was minimized by
utilizing only well trained personnel for the procedures; (2)
No charge; (3) Written informed consent was provided to the
children or the guardians; (4) The participants had the right
to decide whether or not to participate; (5) The participants
in this study will not receive direct benefits from the proposed
research. However, the benefits to society could be a potentially
less expensive and faster way to diagnose a serious disease and
begin treatment earlier than current diagnostic methods.
FIGURE 1 | Different proteins selected through LC-MS/MS analysis. (A)
282 and 76 proteins differed in the MPP group (>2- or <0.5-fold), when
compared to the HC group and IDC group, respectively. Of these, 27 proteins
were overlapping. (B) 18 proteins were down-regulated (<0.5-fold) and 9
proteins were up-regulated (>2-fold) in MPP group when compared to HC
group. (C) 21 proteins were down-regulated (<0.5-fold) and 6 proteins were
up-regulated in MPP group when compared with IDC group.
TABLE 1 | Demographic characteristic of the participants.
Selected period Verification period
MPP HC IDC P-valuea MPP HC IDC P-valuea
Sample size 20 20 17 – 85 95 75 –
Sex (%)
Boy 11 11 9 0.302 42 48 39 0.315
Girl 9 9 8 43 47 36
Age (years)b 6.9 ± 3.0 6.3 ± 3.5 5.6 ± 3.9 0.323 7.0 ± 3.0 7.0 ± 3.0 6.2 ± 5.6 0.082
Age range (years) 1.9–12.4 3–12 1–12 – 1.5–15.1 2.1–17.1 1.9–17.2 –
aP-value among MPP, HC, and IDC.
bData are presented as mean ± SD.
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RESULTS
Characteristics of the Study Population
During the selected period, of 20 children with MPP enrolled in
our study, 11 (55%)were boys. Themean age of the patients in the
MPP group was 6.9 years, ranging from 1.9 to 12.4 years. Among
17 children in the IDC group, the causative agents included
Streptococcus pneumoniae (n = 2), Influenza B virus (n = 3),
Escherichia coli (n = 3), Mycobacterium tuberculosis (n = 2),
Haemophilus (n = 3), and Epstein-Barr virus (n = 4). Regarding
patient demographics, no significant differences in age or gender
were identified among the MPP, HC, and IDC groups.
During the verification period, 85 MPP children, 95 HC and
75 IDC were recruited for ELISA verification. No significant
differences in age or gender were identified among these three
groups (Table 1).
Label-Free Quantitative Proteomic
Analysis
Label-free quantitative proteomics coupled with LC-
MS/MS analysis were used to compare samples from
the three groups (MPP, HC, and IDC). Based on
the LC-MS/MS data, a total of 2777 proteins were
identified.
The analysis results showed that 282 and 76 proteins differed
between the MPP group (>2- or <0.5-fold) and the HC group
and IDC group, respectively (Supplementary Tables 2 and 3).
Of these, 27 overlapping proteins were further analyzed: 18
proteins were down-regulated (<0.5-fold) and 9 proteins were
up-regulated (>2-fold) in the MPP group compared with the
HC group. Twenty-one proteins were down-regulated (<0.5-
fold) and six proteins were up-regulated (>2-fold) in the
MPP group compared with the IDC group (Figure 1 and
Table 2).
To reveal the bio-function relationship among the proteins, a
hierarchical clustering based on Pearson correlation of variances
was applied by R studio. Figure 2 shows the hierarchical
clustering of 27 identified proteins, where an increasing red
color shows increasing protein expression levels (Figure 2).
The most striking area of up-regulation in MPP patients was
indicated by a region with a series of protein peaks (red
color).
TABLE 2 | Proteins identified following LC-MS/MS of MPP different from healthy and disease control fractions.
Gi number Protein name Gene Uniprot identifier Mass pI Scores MPP:HC MPP:IDC
gi|50659080 Alpha-1-antichymotrypsin precursor SERPINA3 P01011 47.6 5.2 279.4 0.386 0.483
gi|7661960 Kinetochore-associated protein 1 KNTC1 P50748 250.6 5.6 127.2 0.069 0.264
gi|63998985 Mitogen-activated protein kinase kinase kinase 19 isoform 3 MAP3K19 Q56UN5 137.5 6.7 123.6 2.174 1.961
gi|93204879 PR domain zinc finger protein 15 isoform 1 PRDM15 P57071 169.2 9.6 123.4 0.233 0.439
gi|31791053 Zinc finger protein 804B ZNF804B A4D1E1 152.5 9.8 116.8 0.178 0.189
gi|4885583 rho-associated protein kinase 1 ROCK1 Q13464 158.1 5.6 113.3 2.941 0.431
gi|572882727 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase
epsilon-1 isoform 3
PLCE1 Q9P212 256.9 6 106.8 0.188 2.000
gi|6912622 DNA repair and recombination protein RAD54B isoform 1 RAD54B Q9Y620 102.9 9.4 98.7 0.300 8.333
gi|33620769 E3 ubiquitin-protein ligase RBBP6 isoform 1 RBBP6 Q7Z6E9 201.4 10.2 89.3 2.174 0.529
gi|108773808 Coiled-coil domain-containing protein 174 CCDC174 Q6PII3 53.9 6 84.6 0.361 0.266
gi|262118216 Coiled-coil domain-containing protein 88B precursor CCDC88B A6NC98 164.7 4.9 83.1 2.273 0.328
gi|140161498 Microtubule-associated tumor suppressor candidate 2
isoform a
MTUS2 Q5JR59 151.1 6.3 82.3 0.503 0.526
gi|44921615 Exocyst complex component 8 EXOC8 Q8IYI6 81.7 5.2 78.1 2.941 0.431
gi|356461016 Gem-associated protein 5 isoform 2 GEMIN5 Q8TEQ6 168.4 6.2 73.6 0.439 0.526
gi|4502157 Apolipoprotein C-I precursor APOC1 P02654 9.3 9.3 73.5 2.083 2.273
gi|302129652 Annexin A6 isoform 2 ANXA6 P08133 72.4 5.3 71.3 0.154 0.103
gi|338753408 Transcription factor IIIB 90 kDa subunit isoform 5 BRF1 Q92994 61.8 5 60.8 0.455 0.372
gi|32967603 Bromodomain adjacent to zinc finger domain protein 1A
isoform a
BAZ1A Q9NRL2 178.6 6.2 59.6 0.538 0.227
gi|321267571 CASP8 and FADD-like apoptosis regulator isoform 6 CFLAR O15519 41.3 7 51.9 0.538 0.493
gi|83700225 Potassium-transporting ATPase alpha chain 2 isoform 2 ATP12A P54707 115.4 6.1 45.4 0.309 0.439
gi|390407643 cAMP-regulated phosphoprotein 21 isoform 4 ARPP21 Q9UBL0 88.5 6.5 41.1 0.439 0.422
gi|284925165 SUN domain-containing protein 1 isoform c SUN1 O94901 76.4 6.2 40.4 2.326 2.778
gi|4507955 Transcriptional repressor protein YY1 YY1 P25490 44.7 5.8 38.1 2.128 0.124
gi|392050772 Zinc finger protein 850 isoform 2 ZNF850 A0A087X0M6 121.8 10.1 37.5 2.041 2.128
gi|149588534 Ataxin-7-like protein 3 isoform b ATXN7L3 Q14CW9 38.6 6.8 36.6 0.278 0.407
gi|222352127 Protein sidekick-2 precursor SDK2 Q58EX2 239.2 6.6 85.3 0.483 0.546
gi|378925630 Ubiquitin carboxyl-terminal hydrolase 17-like protein 10 USP17L10 C9JJH3 59.8 9.4 50.5 0.483 0.546
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FIGURE 2 | Heat map of the 27 identified proteins. The most striking area
of up-regulation in TB patients is seen in the region where a series of protein
peaks showed in red.
Bioinformatic Analysis of Differentially
Expressed Proteins during MP Infection
GO Analysis
GO annotation was used to analyze the functions of the 27
proteins, which were classified into three categories: CC, MF,
and BP. To visualize the annotation of gene sets, WEGO
was used to plot the distribution of GO annotations. The
differentially identified proteins were subcategorized into 35
main hierarchically structured GO classifications including
9 CC, 6 MF, and 20 BP (Figure 3 and Supplementary
Table 4).
The majority of proteins in the CC category had a cellular part
and organelle distribution. The 27 proteins in the MF category
were mainly related to binding, catalysis, enzyme regulator,
molecular transducer, transcription regulator, and transporter.
The 27 proteins in the BP category were mainly associated
with cellular processes, metabolic processes, cellular component
organization, biological regulation, and pigmentation. This
analysis indicated that the identified proteins involved in these
GO categories might have the most important roles in the MP
infection process.
KEGG Enrichment Analysis
To obtain more information with regards to the markers,
a pathway analysis was conducted using KEGG. Using a
standard of P < 0.05 and impact factor threshold >0, the
pathway analysis results demonstrated that the cAMP signaling
pathway (P = 0.026) and proteoglycans in cancer (P = 0.028)
were significantly associated with MPP infection (Figure 4 and
Supplementary Table 5).
Identification of Novel Biomarkers for the
Differentiate of MPP
Validation of Identified Proteins by ELISA
Based on the bioinformatics analysis, five potential candidate
biomarkers (APOC1, SERPINA3, ANXA6, KNTC1, and CFLAR)
were selected for verification (Figure 5 and Supplementary
Table 6). The selection principles were based on the following
standards: (1) high fold change; (2) representative in the 27
proteins; (3) associated with immunity or infectious diseases;
and (4) present the same trends when compared with the HC
and IDC.
Significant differences in SERPINA3, APOC1, and CFLAR
levels were observed among all three groups and their ratios were
consistent with the trends of the proteomic results (P < 0.001,
0.001, and 0.008, respectively). As shown in Figure 5, the level of
APOC1 protein in MPP was markedly increased when compared
with that in HC or IDC. In contrast, significantly lower levels
of the two proteins (SERPINA3 and CFLAR) were observed in
the MPP group compared with that in HC or IDC. Although
the levels of ANXA6 and KNTC1 were lower in the MPP group
compared with the HC group, there were no differences between
the MPP and IDC patients.
Performance of Each Selected Protein to
Differentiate of MPP
The AUC, sensitivity, and specificity of ROC curves calculated
at optimal cutoffs for the three different proteins are shown in
Table 3. A comparison of MPP patients and HC showed APOC1
had the largest AUC of 0.853, with 77.6% sensitivity and 81.1%
specificity. The comparison of MPP and IDC patients showed
APOC1 had a relatively high AUC of 0.882, with 77.6% sensitivity
and 85.3% specificity. SERPINA3 and CFLAR had AUC-values
of 0.739 and 0.524 when MPP patients were compared with
HC, respectively, and they had lower AUC-values of 0.643
and 0.647 when compared between MPP and IDC patients,
respectively. In addition, we combined the HC and IDC for
further analysis. APOC1, SERPINA3, and CFLAR had AUC-
values of 0.866, 0.698, and 0.578 when MPP was compared with
HC plus IDC, respectively. Our results showed that the APOC1 in
MPP group presented the best AUC among these three proteins
when compare with HC, IDC, or HC combined with IDC.
Sensitivities and Specificities of Combinations of
Selected Proteins
Using the same optimal cutoffs for each protein, we calculated
the sensitivities and specificities of combinations of two or three
selected proteins to differentiate MPP. As shown in Table 4,
although the specificities of combined proteins were generally
higher than APOC1, the sensitivities of the combined proteins
were lower than this best protein for discriminatingMPP patients
from HC or IDC patients. Combined with the performance of
each selected protein to differentiate of MPP, the results showed
that APOC1 alone was the best choice in children.
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FIGURE 3 | Gene Ontology (GO) classification of differentially expressed proteins by label-free Quantitative Proteomics experiments between MPP
and controls. The differentially expressed proteins are grouped into three hierarchically structured GO terms: biological process, cellular component, and molecular
function. The y-axis indicates the number and percent of proteins in each GO term.
DISCUSSION
Immune responses, induced by MP infection, have an important
effect on pathogenic mechanisms and protein expression.
Traditionally, proteins appear in the circulation through many
different mechanisms including secretion after subjects are
infected by a pathogen, when production is stimulated by
antigens, or by direct secretion by MP (Li et al., 2014). Recently,
high-throughput technologies have been used to investigate
protein expression, and therefore, the accurate detection and
quantification of these MP-associated proteins can be used as
potential diagnostic markers.
Previous methods used to detect MPs had limitations
(Daxboeck et al., 2003; Long et al., 2012; Yuta et al., 2014;
Katsushima et al., 2015). In clinical practice, co-infections
are common in children with pneumonia. Therefore, in this
study, HC and IDC were both used as controls. By using
label-free quantitative analysis, we analyzed plasma proteins
among MPP, HC, and IDC individuals. This proteomic approach
allowed the measurement of changes in protein expression,
which might be used to “forecast” disease pathogenesis. As
reported here, 282 and 76 proteins were identified in the MPP
group compared with the HC and IDC groups, of which 27
were overlapping. In addition, WEGO was used to analysis
the function of the 27 different proteins. Here, we observed
that a majority of the proteins had a cellular distribution
and organelles. They were mainly related to binding, catalysis,
enzyme regulator, molecular transducer, transcription regulator,
and transporter. They mostly participated in cellular processes,
metabolic processes, cellular component organization, biological
regulation, and pigmentation, all of which are thought to be
essential in the pathogenesis of MP.
Among the 27 proteins identified, five potential candidate
biomarkers (SERPINA3, KNTC1, APOC1, ANXA6, and CFLAR)
were selected for verification because they correlated with
immune responses in other infectious diseases. However, ELISA
showed that only the levels of SERPINA3, APOC1, and CFLAR
were significantly different among all three groups and their
ratios were consistent with the trends of the proteomics analyses.
Using the same optimal cutoffs for each protein, we analyzed
the sensitivities and specificities of different combinations of
two or three of the different proteins for the diagnosis of MPP.
The specificities of combined proteins were generally higher
than APOC1, while the sensitivities of combined proteins were
generally lower than the best protein for differentiating MPP
patients andHC or IDC patients. In summary, our results showed
that APOC1 alone was the best choice for differentiate of MPP
in children. APOC1 had the best sensitivity and specificity. To
the best of our knowledge, the sensitivity and specificity of
the MP-specific antigens currently used are poor when used
as a diagnostic test based on ineffective antibody detection
(Zhang et al., 2014). Li et al. (2014) used label-free quantitative
proteomics to demonstrate that IL-33 production in A549 cells
was increased when they were infected with MP. They also found
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FIGURE 4 | KEGG enrichment analysis of the differential expressed proteins.
FIGURE 5 | Five selected proteins different between ATB and LTBI were
analyzed by ELISA (MPP = 85, HC = 95, IDC = 75). Significant differences
in SERPINA3, APOC1, and CFLAR levels were noted among all three groups
and their ratios were consistent with the trends of proteomics results. Data are
presented as means ± SD. *p < 0.05; **p < 0.01; ***p < 0.001
that IL-33 levels were higher in MPP patients with sensitivity
and specificity accuracy of 70.0 and 73.3%, respectively (Li
et al., 2014). However, larger sample sizes are needed for further
identification and quantification.
MP is a unique cell wall deficient and cholesterol requiring
bacteria (Berbée et al., 2005; Ko et al., 2014). Cholesterol
metabolism is essential for MP growth and infection. APOC1
is a 6.6-kDa plasma protein that inhibits receptor-mediated
lipoprotein clearance (Shulman et al., 1975). It is secreted by
many organs, including the liver, spleen, and lung, and is secreted
into the blood (Lauer et al., 1988). Therefore, the plasma level
of APOC1 is associated with cholesterol metabolism and MP
infection status in humans. Lipid metabolism is one of the
essential changes in many infectious diseases, including MPP
(Katsel et al., 2007; Xiang et al., 2007). Furthermore, many
cholesterol metabolites have been analyzed by studies with the
aim of screening and identifying early biomarkers for infectious
disease (Leoni et al., 2006; Bach et al., 2009; Gilch et al., 2009).
Several genes associated with cholesterol metabolism and lipid
biosynthesis were reported to be up-regulated in serum or
plasma (Brown et al., 2005). Because APOC1 activates cholesterol
metabolism (Barbisin et al., 2014), its up-regulation leads to
an increase in cholesterol biosynthesis, consistent with the
concomitant presence of MP infectious disease.
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TABLE 3 | AUC, sensitivity, and specificity for ROC curves calculated at optimal cutoff for SERPINA3, APOC1, and CFLAR.
Significant proteins by comparison groups AUC 95% CI Sensitivity (%) Specificity (%) P-value Log2 FC
MPP vs. HC
APOC1 0.853 0.796–0.907 77.6 81.1 8.81E–18 0.56
SERPINA3 0.739 0.662–0.818 77.6 68.4 1.38E–7 −0.34
CFLAR 0.524 0.436–0.61 77.6 42.1 7.56 E–3 0.12
MPP vs. IDC
APOC1 0.882 0.834–0.93 77.6 85.3 1.37E–18 0.78
SERPINA3 0.643 0.558–0.735 72.9 65.3 2.15E–3 −0.33
CFLAR 0.647 0.55–0.733 81.2 50.7 1.54 E–3 −0.66
MPP vs. (HC + IDC)
APOC1 0.866 0.816–0.915 77.6 82.9 1.34E–26 0.55
SERPINA3 0.698 0.624–0.763 77.6 64.7 1.42E–6 −0.05
CFLAR 0.578 0.514–0.648 71.8 54.1 3.74 E–3 −0.64
TABLE 4 | Sensitivities and specificities of combinations of two or three proteins for differentiation between MPP and HC, IDC, or HC + IDC.
Proteins MPP vs. HC MPP vs. IDC MPP vs. HC + IDC
Sensitivity (%) Specificity (%) Sensitivity (%) Specificity (%) Sensitivity (%) Specificity (%)
APOC1 + SERPINA3 76.5 87.4 76.5 85.3 77.7 82.9
APOC1 + CFLAR 75.3 82.1 76.5 81.3 75.3 81.8
SERPINA3 + CFLAR 75.3 68.4 74.1 58.7 75.3 67.1
SERPINA3 + APOC1 + CFLAR 74.1 84.2 78.8 81.3 77.7 83.5
Our study demonstrated that APOC1 alone is a potential
biomarker for differentiate of MPP in children. This was an
exploratory study to detect novel plasma proteomics biomarkers
and further studies are required. MPP causes up to 40% of
CAP in children and biomarker selection requires a large
sample verification. Clearly, this should be the focus of further
investigations.
In conclusion, 27 potential MPP plasma biomarkers were
identified using LC-MS/MS. After ELISA verification, APOC1
was identified with satisfactory sensitivity and specificity to
discriminate MPP from HC or IDC, and represents a viable
approach for the differentiate of MPP.
AUTHOR CONTRIBUTIONS
JL and AS designed the experiments. JL and LS performed
the experiments and analyzed the data. FX, WJ, and HQ
provided technical support for the experiments. AS, JX, and CS
provided comments and technical advice. JL, LS, and AS wrote
the manuscript. JL, BX, and QL revised the manuscript. All
authors discussed the results, commented on the manuscript,
and agreed to be accountable for all aspects of the work in
ensuring that questions related to the accuracy or integrity
of any part of the work are appropriately investigated and
resolved.
FUNDING
This work was supported by grants from Beijing Natural
Science Foundation (No. 7164257), Capital Health Research
and Development of Special Grant (No. 2016-1-2092),
the BeiJing Talents Fund (No. 2014000021469G244), and
collaborative Innovation Center of Infectious Diseases (No.
PXM2014_014226_000011).
ACKNOWLEDGMENTS
We thank all the authors in this manuscript.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: http://journal.frontiersin.org/article/10.3389/fmicb.
2016.01961/full#supplementary-material
REFERENCES
Agranoff, D., Fernandez-Reyes, D., Papadopoulos, M. C., Rojas, S.
A., Herbster, M., Loosemore, A., et al. (2006). Identification of
diagnostic markers for tuberculosis by proteomic fingerprinting
of serum. Lancet 368, 1012–1021. doi: 10.1016/S0140-6736(06)
69342-2
Bach, C., Gilch, S., Rost, R., Greenwood, A. D., Horsch,M., Hajj, G. N., et al. (2009).
Prion-induced activation of cholesterogenic gene expression by Srebp2 in
neuronal cells. J. Biol. Chem. 284, 31260–31269. doi: 10.1074/jbc.M109.004382
Frontiers in Microbiology | www.frontiersin.org 8 December 2016 | Volume 7 | Article 1961
Li et al. Mycoplasma pneumoniae and Differentiate
Barbisin, M., Vanni, S., Schmädicke, A. C., Montag, J., Motzkus, D., Opitz, L.,
et al. (2014). Gene expression profiling of brains from bovine spongiform
encephalopathy (BSE)-infected cynomolgus macaques. BMC Genomics 15:434.
doi: 10.1186/1471-2164-15-434
Berbée, J. F., Havekes, L. M., and Rensen, P. C. (2005). Apolipoproteins modulate
the inflammatory response to lipopolysaccharide. J. Endotoxin Res. 11, 97–103.
doi: 10.1179/096805105X35215
Brown, A. R., Rebus, S., McKimmie, C. S., Robertson, K., Williams, A.,
and Fazakerley, J. K. (2005). Gene expression profiling of the preclinical
scrapie-infected hippocampus. Biochem. Biophys. Res. Commun. 334, 86–95.
doi: 10.1016/j.bbrc.2005.06.060
Chen, Z. R., Zhang, G. B., Wang, Y. Q., Yan, Y. D., Zhou, W. F., Zhu,
C. H., et al. (2013). Soluble B7-H3 elevations in hospitalized children
with Mycoplasma pneumoniae pneumonia. Diagn. Microbiol. Infect. Dis. 77,
362–366. doi: 10.1016/j.diagmicrobio.2013.09.006
Covani, U., Marconcini, S., Giacomelli, L., Sivozhelevov, V., Barone, A., and
Nicolini, C. (2008). Bioinformatic prediction of leader genes in human
periodontitis. J. Periodontol. 79, 1974–1983. doi: 10.1902/jop.2008.080062
Daxboeck, F., Krause, R., and Wenisch, C. (2003). Laboratory diagnosis
of Mycoplasma pneumoniae infection. Clin. Microbiol. Infect. 9, 263–273.
doi: 10.1046/j.1469-0691.2003.00590.x
Engwegen, J. Y., Gast, M. C., Schellens, J. H., and Beijnen, J. H.
(2006). Clinical proteomics: searching for better tumor markers with
SELDI-TOF mass spectrometry. Trends Pharmacol. Sci. 27, 251–259.
doi: 10.1016/j.tips.2006.03.003
Gilch, S., Bach, C., Lutzny, G., Vorberg, I., and Schatzl, H. M. (2009). Inhibition of
cholesterol recycling impairs cellular PrPSc propagation. Cell. Mol. Life Sci. 66,
3979–3991. doi: 10.1007/s00018-009-0158-4
Hodgetts, A., Levin, M., Kroll, J. S., and Langford, P. R. (2007). Biomarker
discovery in infectious diseases using SELDI. Future Microbiol. 2, 35–49.
doi: 10.2217/17460913.2.1.35
Hong, M., Zhang, X., Hu, Y.,Wang, H., He,W., Mei, H., et al. (2009). The potential
biomarkers for thromboembolism detected by SELDI-TOF-MS. Thromb. Res.
123, 556–564. doi: 10.1016/j.thromres.2008.05.019
Kanehisa, M., Goto, S., Kawashima, S., Okuno, Y., and Hattori, M. (2004). The
KEGG resourcefor deciphering the genome. Nucleic Acids Res. 32, 277–280.
doi: 10.1093/nar/gkh063
Katsel, P., Li, C., and Haroutunian, V. (2007). Gene expression alterations in
the sphingolipid metabolism pathways during progression of dementia and
Alzheimer’s disease: a shift toward ceramide accumulation at the earliest
recognizable stages of Alzheimer’s disease? Neurochem. Res. 32, 845–856.
doi: 10.1007/s11064-007-9297-x
Katsushima, Y., Katsushima, F., Suzuki, Y., Seto, J., Mizuta, K., Nishimura, H.,
et al. (2015). Characteristics ofMycoplasma pneumoniae infection identified on
culture in a pediatric clinic. Pediatr. Int. 57, 247–252. doi: 10.1111/ped.12513
Ko, H. L., Wang, Y. S., Fong, W. L., Chi, M. S., Chi, K. H., and Kao, S. J.
(2014). Apolipoprotein C1 (APOC1) as a novel diagnostic and prognostic
biomarker for lung cancer: a marker phase I trial. Thorac. Cancer 5, 500–508.
doi: 10.1111/1759-7714.12117
Lauer, S. J., Walker, D., Elshourbagy, N. A., Reardon, C. A., Levy-Wilson, B., and
Taylor, J. M. (1988). Two copies of the human apolipoprotein C-I gene are
linked closely to the apolipoprotein E gene. J. Biol. Chem. 263, 7277–7286.
Lee, J., Kim, S. H., Choi, D. S., Lee, J. S., Kim, D. K., Go, G., et al. (2015). Proteomic
analysis of extracellular vesicles derived from Mycobacterium tuberculosis.
Proteomics 15, 3331–3337. doi: 10.1002/pmic.201500037
Leoni, V., Shafaati, M., Salomon, A., Kivipelto, M., Bjorkhem, I., and Wahlund,
L. O. (2006). Are the CSF levels of 24S-hydroxycholesterol a sensitive
biomarker for mild cognitive impairment? Neurosci. Lett. 397, 83–87.
doi: 10.1016/j.neulet.2005.11.046
Li, S., Li, X., Wang, Y., Yang, J., Chen, Z., and Shan, S. (2014). Global
secretome characterization of A549 human alveolar epithelial carcinoma
cells during Mycoplasma pneumoniae infection. BMC Microbiol. 7:27.
doi: 10.1186/1471-2180-14-27
Long, S. S., Pickering, L. K., and Prober, C. G. (2012). Principles and Practice of
Pediatric Infectious Diseases, 4th Edn. London: Elsevier Churchill Livingstone.
Meyer Sauteur, P. M., Jacobs, B. C., Spuesens, E. B., Jacobs, E., Nadal, D.,
Vink, C., et al. (2014). Antibody responses to Mycoplasma pneumoniae: role
in pathogenesis and diagnosis of encephalitis? PLoS Pathog. 10:e1003983.
doi: 10.1371/journal.ppat.1003983
Papadopoulos, M. C., Abel, P. M., Agranoff, D., Stich, A., Tarelli, E., Bell, B. A., et al.
(2004). A novel and accurate test for Human African Trypanosomiasis. Lancet
363, 1358–1363. doi: 10.1016/S0140-6736(04)16046-7
Pinet, F., Beseme, O., Cieniewski-Bernard, C., Drobecq, H., Jourdain, S.,
Lamblin, N., et al. (2008). Predicting left ventricular remodeling after a first
myocardial infarction by plasma proteome analysis. Proteomics 8, 1798–1808.
doi: 10.1002/pmic.200700781
Ren, Y., He, Q. Y., Fan, J., Jones, B., Zhou, Y., Xie, Y., et al. (2004).
The use of proteomics in the discovery of serum biomarkers from
patients with severe acute respiratory syndrome. Proteomics 4, 3477–3484.
doi: 10.1002/pmic.200400897
Sanchez-Vargas, F. M., and Gomez-Duarte, O. G. (2008). Mycoplasma
pneumoniae-an emerging extra-pulmonary pathogen. Clin. Microbiol.
Infect. 14, 105–117. doi: 10.1111/j.1469-0691.2007.01834.x
Shu, L. H., Lu, Q., Han, L. Y., and Dong, G. H. (2015). SP-D, KL-6, and HTI-56
levels in children with Mycoplasma pneumoniae pneumonia. Int. J. Clin. Exp.
Pathol. 8, 11185–11191.
Shulman, R. S., Herbert, P. N., Wehrly, K., and Fredrickson, D. S. (1975). Thf
complete amino acid sequence of C-I (apoLp-Ser), an apolipoprotein from
human very low density lipoproteins. J. Biol. Chem. 250, 182–190.
Sun, G., Xu, X., Wang, Y., Shen, X., Chen, Z., and Yang, J. (2008). Mycoplasma
pneumonia infection induces reactive oxygen species and DNA damage
in A549 human lung carcinoma cells. Infect. Immun. 76, 4405–4413.
doi: 10.1128/IAI.00575-08
Tamura, A., Matsubara, K., Tanaka, T., Nigami, H., Yura, K., and Fukaya, T. (2008).
Methylprednis-olone pulse therapy for refractory Mycoplasma pneumoniae
pneumonia in children. J. Infect. 57, 223–228. doi: 10.1016/j.jinf.2008.06.012
Waites, K., and Talkington, D. (2004). Mycoplasma pneumoniae and
its role as a human pathogen. Clin. Microbiol. Rev. 17, 697–728.
doi: 10.1128/CMR.17.4.697-728.2004
Wang, M., Wang, Y., Yan, Y., Zhu, C., Huang, L., Shao, X., et al. (2014). Clinical
and laboratory profiles of refratory Mycoplasma penumoniae pneumonia in
children. Int. J. Infec. Dis. 29, 18–23. doi: 10.1016/j.ijid.2014.07.020
Wu, L., Tian, L., Wang, S., Zhang, J., Liu, P., Tian, Z., et al. (2016). Comparative
proteomic analysis of the response of maize (Zea mays L.) leaves to
long photoperiod condition. Front. Plant. Sci. 7:752. doi: 10.3389/fpls.2016.
00752
Xiang, W., Hummel, M., Mitteregger, G., Pace, C., Windl, O., Mansmann, U., et al.
(2007). Transcriptome analysis reveals altered cholesterol metabolism during
the neurodegeneration in mouse scrapie model. J. Neurochem. 102, 834–847.
doi: 10.1111/j.1471-4159.2007.04566.x
Yuta, A., Tomohiro, O., Shinya, T., Tetsuo, T., and Akihiko, S. (2014).
Clinical utility of loop-mediated isothermal amplification for rapid diagnosis
of Mycoplasma pneumoniae in children. J. Med. Microbiol. 63, 248–251.
doi: 10.1099/jmm.0.068288-0
Zhang, X., Guo, T., Wang, H., He, W., Mei, H., Hong, M., et al. (2008).
Potential biomarkers of acute cerebral infarction detected by SELDI-
TOF-MS. Am. J. Clin. Pathol. 130, 299–304. doi: 10.1309/CA242R5VY1
4HUGE8
Zhang, X., Li, W., Hou, Y., Niu, Z., Zhong, Y., Zhang, Y., et al. (2014).
Comparative membrane proteomic analysis between lung adenocarcinoma
and normal by iTRAQ labeling mass spectrometry. Am. J. Transl. Res. 6,
267–280.
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Li, Sun, Xu, Qi, Shen, Jiao, Xiao, Li, Xu and Shen. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) or licensor are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these
terms.
Frontiers in Microbiology | www.frontiersin.org 9 December 2016 | Volume 7 | Article 1961
